EcoDrugPlus

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSMMDG00005018083
Gene Symbol: FYN
3 Cross references
196 Possible Orthologues:

G Protein-Coupled Receptor 119

Ensembl ID : ENSMMDG00005016295
Gene Symbol: GPR119
3 Cross references
174 Possible Orthologues:

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSMMDG00005005694
Gene Symbol: HCK
1 Cross references
202 Possible Orthologues:

Il2 Inducible T Cell Kinase

Ensembl ID : ENSMMDG00005022526
Gene Symbol: ITK
1 Cross references
206 Possible Orthologues:

Imp (Inosine 5'-Monophosphate) Dehydrogenase 1a

Ensembl ID : ENSMMDG00005017703
Gene Symbol: IMPDH1A
1 Cross references
258 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSMMDG00005017951
Gene Symbol: JAK1
3 Cross references
212 Possible Orthologues:

Janus Kinase 2a

Ensembl ID : ENSMMDG00005012944
Gene Symbol: JAK2A
1 Cross references
199 Possible Orthologues:

Kit Proto-Oncogene, Receptor Tyrosine Kinase B

Ensembl ID : ENSMMDG00005003764
Gene Symbol: KITB
1 Cross references
200 Possible Orthologues:

Kras Proto-Oncogene, Gtpase

Ensembl ID : ENSMMDG00005023686
Gene Symbol: KRAS
3 Cross references
207 Possible Orthologues:

Malt1 Paracaspase

Ensembl ID : ENSMMDG00005008972
Gene Symbol: MALT1
2 Cross references
195 Possible Orthologues:

Map Kinase-Activated Protein Kinase 2-Like

Ensembl ID : ENSMMDG00005010785
Gene Symbol: LOC115362355
3 Cross references
174 Possible Orthologues:

Map Kinase-Interacting Serine/threonine-Protein Kinase 2-Like

Ensembl ID : ENSMMDG00005004720
Gene Symbol: LOC115357572
3 Cross references
208 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).